El tratamiento se inicia con la dosis ms baja durante el primer mes y, por lo general, se va aumentando hasta alcanzar la dosis ms alta al cabo de 5 meses
Minerva Urol.Nefrol
Methods 184 , 3951 (1995)
Using propensity-score matched analysis results showed that who were treated with a GLP-1 receptor agonist at 1 year VTE rates were 20% lower when compared to patients on a DDP-4 inhibitor
However, as safety signals around NAION have emerged, a growing number of filings and investigations now involve vision loss claims , including: Sudden, severe vision changes or permanent vision loss while on a GLP-1 drug Diagnosed NAION or other optic nerve injuries temporally linked to starting or escalating the medication Allegations that manufacturers failed to timely investigate, disclose, and warn about the risk of NAION, even as case reports and safety data accumulated Some vision-loss cases may proceed within or alongside the existing MDL, while others may be filed in state courts or as individual federal actions, depending on the facts and strategy
